Industry Trends

Latest stories

13 Shares

5 Lessons Learned from the Pandemic for Commercial Life Sciences with Insights from Novartis

7 Shares

A Year of Digital-First Engagement

By The Numbers

Trending Now

1.1k Views0 Comments
in Headlines

Asher Bio Closes $108 Million Series B Financing

South San Francisco, CA, September 1, 2021 (Business Wire) — Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of an oversubscribed Series B financing, which raised $108 million. The financing was led by Wellington Management Company LLP, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors. More

by hsandm September 1, 2021, 2:54 pm

Read More
1.1k Views0 Comments
in Headlines

Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer

Natick, MA. & Shangai, September 1, 2021 (Business Wire) — Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Randy Pritchard as Chief Executive Officer. The company’s founder, industry veteran and renowned scientific innovator, Gang Song, Ph.D., will transition to the role of Chairman of the Board, where he will be responsible for leading the Board, ensuring governance standard and focusing on all strategic matters for Pillar Biosciences. In his new role as CEO, Mr. Pritchard will look to accelerate the company’s efforts to make precision oncology accessible for all patients throughout the patient journey. More

by hsandm September 1, 2021, 2:33 pm

Read More
1 Shares1.2k Views0 Comments
in Headlines

Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Boston and Houston, August 30, 2021 (GLOBE Newswire) — Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the appointment of Kevin S. Boyle, Sr. as its new Chief Executive Officer, effective today. As previously planned, Heidi Hagen, Interim CEO, is returning to her position as a member of the Board of Directors (the “Board”). Mr. Boyle has also been named to the Board. In addition, today the Company has announced promotions within its senior leadership. More

by hsandm August 30, 2021, 2:42 pm

Read More
1.6k Views0 Comments
in Headlines

Baxter in advanced talks to acquire Hill-Rom for $10 billion -source

Deerfield, IL, August 30 2021 (Reuters) — U.S.-based medical technology company Baxter International Inc (BAX.N) is nearing a deal to buy medical equipment maker Hill-Rom Holdings Inc (HRC.N) for more than $10 billion, a person familiar with the matter said on Monday. More

by hsandm August 30, 2021, 2:18 pm

Read More
1.7k Views0 Comments
in Headlines

Seattle biotech firm Shape Therapeutics inks gene therapy deal with Roche worth up to $3B

Seattle, August 24, 2021 (Globe Newswire) — Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced a multi-target strategic collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). Through this partnership ShapeTX will apply its proprietary RNA editing platform RNAfix™ and potentially leverage its AAVid™ technology platform for next-generation tissue-specific adeno-associated viruses (AAVs) for the development of gene therapy for certain targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases. More

by hsandm August 24, 2021, 3:18 pm

Read More
2.2k Views0 Comments
in Headlines

Immunitas Therapeutics Completes $58 Million Series B Financing

Waltham, MA., August 18, 2021 (PRNewswire) — Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). More

by hsandm August 18, 2021, 6:45 pm

Read More

Industry Trends

Latest stories

5 Lessons Learned from the Pandemic for Commercial Life Sciences with Insights from Novartis

A Year of Digital-First Engagement

By The Numbers

More stories

BioPharma’s COVID-19 Response, Market Forecast & M&A

Industry Trends: By the numbers

Beyond COVID-19: Life sciences reimagined

By the numbers

Pharma, Biotech and MedTech Half-Year Review from Evaluate Vantage

Industry Trends: By the numbers

The Orphan Drug Outlook

Metrics on Covid-19: Highlights of the Evaluate Vantage Report

INDUSTRY TRENDS: BY THE NUMBERS

Life Science Industry Outlook: 2019 In Review and 2020 Trends to Watch

INDUSTRY TRENDS: BY THE NUMBERS

VANTAGE 2020 PREVIEW

Asher Bio Closes $108 Million Series B Financing

Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer

Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Baxter in advanced talks to acquire Hill-Rom for $10 billion -source

Seattle biotech firm Shape Therapeutics inks gene therapy deal with Roche worth up to $3B

Immunitas Therapeutics Completes $58 Million Series B Financing

Latest stories

More stories

Log In

Sign In

Forgot password?

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections